Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease-Reference-Cited by-同舟云学术

Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease

Published:2019-09 Issue:3 Volume:1 Page:188-198
ISSN:2589-5559
Container-title:JHEP Reports
language:en
Short-container-title:JHEP Reports

Author:

Boyle Marie,Tiniakos Dina,Schattenberg Jorn M.,Ratziu Vlad,Bugianessi Elisabetta,Petta Salvatore,Oliveira Claudia P.,Govaere Olivier,Younes Ramy,McPherson Stuart,Bedossa Pierre,Nielsen Mette J,Karsdal Morten,Leeming Diana,Kendrick Stuart,Anstee Quentin M.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology,Immunology and Allergy,Internal Medicine

Reference55 articles.

1. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis;Anstee;Nat Rev Gastroenterol Hepatol,2013

2. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis;Dulai;Hepatology,2017

3. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease;Angulo;Gastroenterology,2015

4. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies;Singh;Clin Gastroenterol Hepatol,2015

5. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management;McPherson;J Hepatol,2015

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease;Diabetes & Metabolism Journal;2024-07-31

2. A roadmap for clinical trials in MASH-related compensated cirrhosis;Nature Reviews Gastroenterology & Hepatology;2024-07-17

3. Metabolic dysfunction−associated liver disease and diabetes: Matrix remodeling, fibrosis, and therapeutic implications;Annals of the New York Academy of Sciences;2024-07-12

4. Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated Steatohepatitis;Seminars in Liver Disease;2024-07-09

5. Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis;Hepatology Communications;2024-07